Stoke Therapeutics, Inc. (STOK)
Automate Your Wheel Strategy on STOK
With Tiblio's Option Bot, you can configure your own wheel strategy including STOK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol STOK
- Rev/Share 3.2993
- Book/Share 6.8223
- PB 1.6082
- Debt/Equity 0.0
- CurrentRatio 8.4085
- ROIC 0.103
- MktCap 531227837.0
- FreeCF/Share 1.1959
- PFCF 7.6768
- PE 11.1992
- Debt/Assets 0.0
- DivYield 0
- ROE 0.1908
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | STOK | Chardan Capital Markets | -- | Buy | -- | $24 | Dec. 20, 2024 |
| Resumed | STOK | Leerink Partners | -- | Outperform | -- | $18 | Oct. 14, 2024 |
News
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year ago.
Read More
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Stoke Therapeutics Stock Slips as CEO Steps Down
Published: March 18, 2025 by: Investopedia
Sentiment: Negative
Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.
Read More
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.
Read More
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
Published: February 26, 2025 by: Business Wire
Sentiment: Neutral
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Wednesday, March 5, 2025 Time: 9:50 a.m. ET Leerink Partners Global Healthcare Conference Date: Monday, March 10, 2025 Time: 10:40 a.m. ET Live webcasts of each ev.
Read More
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties CAMBRIDGE, Mass. and BEDFORD, Mass.
Read More
About Stoke Therapeutics, Inc. (STOK)
- IPO Date 2019-06-19
- Website https://www.stoketherapeutics.com
- Industry Biotechnology
- CEO Mr. Ian F. Smith A.C.A., C.P.A.
- Employees 128